Checkpoint Therapeutics (NASDAQ:CKPT) Releases Earnings Results, Misses Expectations By $0.47 EPS

Checkpoint Therapeutics (NASDAQ:CKPT) released its quarterly earnings data on Friday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.47), Zacks reports.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ CKPT traded up $0.01 during midday trading on Friday, hitting $4.04. 522,554 shares of the company’s stock were exchanged, compared to its average volume of 1,124,079. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The stock’s 50 day moving average price is $3.32 and its 200-day moving average price is $3.25. The firm has a market cap of $197.29 million, a P/E ratio of -2.20 and a beta of 1.41.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. HC Wainwright reaffirmed a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. D. Boral Capital restated a “buy” rating and set a $4.80 target price (down previously from $9.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. Finally, Lake Street Capital reaffirmed a “hold” rating and issued a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th.

Insider Buying and Selling at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 74,110 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the transaction, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at approximately $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO James F. Oliviero III sold 10,331 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.15, for a total transaction of $32,542.65. Following the completion of the sale, the chief executive officer now owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. This represents a 0.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,674 shares of company stock valued at $336,011. Company insiders own 2.10% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.